Publication Cover
Orbit
The International Journal on Orbital Disorders, Oculoplastic and Lacrimal Surgery
Volume 38, 2019 - Issue 3
161
Views
3
CrossRef citations to date
0
Altmetric
Case Report

Botulinum toxin-B injection into the lacrimal gland and posterior cricoarytenoid muscle for the treatment of epiphora and abductor spasmodic dysphonia secondary to Parkinson’s disease

, &
Pages 248-251 | Received 18 Apr 2018, Accepted 13 Jun 2018, Published online: 25 Jun 2018

References

  • Bentivoglio AR, Del Grande A, Pentracca M, Ialongo T, Ricciardi L. Toxicon. 2015;107(PtA):77–84. doi:10.1016/j.toxicon.2015.08.001.
  • Boroojerdi B, Ferbert A, Schwarz M, et al. Botulinum toxin treatment of synkinesia and hyperlacrimation after facial palsy. J Neurol Neurosurg Psychiatry. 1998;65:111–114. doi:10.1136/jnnp.65.1.111.
  • Wojno TH. Results of lacrimal gland botulinum toxin injection for epiphora in lacrimal obstruction and gustatory tearing. Ophthal Plast Reconstr Surg. 2011;27:119–121. doi:10.1097/IOP.0b013e318201d1d3.
  • Kaynak P, Karabulut GO, Ozturker C, et al. Comparison of botulinum toxin-A injection in lacrimal gland and conjunctivodacryocystorhinostomy for treatment of epiphora due to proximal lacrimal system obstruction. Eye (Lond). 2016;30:1056–1062. doi:10.1038/eye.2016.88.
  • Girard B, Piaton JM, Keller P, et al. Botulinum neurotoxin injection for the treatment of epiphora in nasolacrimal duct obstruction. J Fr Ophtalmol. 2017;40(8):661–665. doi:10.1016/j.jfo.2017.03.006.
  • Whittaker KW, Matthews BN, Fitt AW, Sandramouli S. The use of botulinum toxin A in the treatment of functional epiphora. Orbit. 2003;22:193–198. doi:10.1076/orbi.22.3.193.15622.
  • Blitzer A, Brin MF, Stewart CF. Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-year experience in more than 900 patients. Laryngoscope. 1998;108:1435–1441.
  • Hirano M. Clinical Examination of Voice. Disorders of Human Communication. Wien, New York: Springer-Verlag; 1981:xi, 100.
  • Adler CH, Bansberg SF, Krein-Jones K, Hentz JG. Safety and efficacy of botulinum toxin type B (Myobloc) in adductor spasmodic dysphonia. Mov Disord. 2004 September;19(9):1075–1079. doi:10.1002/mds.20098.
  • Woodson G, Hochstetler H, Murry T. Botulinum toxin therapy for abductor spasmodic dysphonia. J Voice. 2006 March;20(1):137–143. doi:10.1016/j.jvoice.2005.03.008.
  • Stephan F, Habre M, Tomb R. Clinical resistance to three types of botulinum toxin type A in aesthetic medicine. J Cosmet Dermatol. 2014 December;13(4):346–348. doi:10.1111/jocd.12108.
  • Marsden CD, Obeso JA, Zarranz JJ, Lang AE. The anatomical basis of symptomatic hemidystonia. Brain. June 1985;108(Pt 2):463–483.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.